Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 13/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969716 | 0.87 | ACLY (0.44) | ACLYNOTUMNPY5RNPC1L1 | |
| SCHEMBL25281852 | 0.83 | MEN1 (0.54) | ACLYNOTUMNPY5RMEN1KMT2A | |
| SCHEMBL29386556 | 0.83 | MEN1 (0.54) | ACLYNOTUMNPY5RMEN1KMT2A | |
| SCHEMBL25276068 | 0.79 | KMT2A (0.43) | ACLYNOTUMMEN1KMT2AATM | |
| SCHEMBL26969753 | 0.79 | ACLY (0.41) | ACLYNOTUMNPY5RNPC1L1 | |
| SCHEMBL30733431 | 0.78 | KDM2B (0.43) | ACLYNOTUMNPY5RMEN1KMT2A | |
| SCHEMBL30733423 | 0.77 | KCNN4 (0.47) | ACLYNOTUMKMT2AL3MBTL1 | |
| SCHEMBL30733401 | 0.77 | NOTUM (0.45) | ACLYNOTUMNPY5R | |
| SCHEMBL30733408 | 0.76 | KMT2A (0.43) | ACLYNOTUMNPY5RKMT2A | |
| SCHEMBL30733405 | 0.76 | TSHR (0.50) | ACLYNOTUMMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | ACLY 3265/4885NOTUM 2050/4885NPY5R 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.